Trastuzumab deruxtecan (T-DXd) was approved in Japan for HER2-positive solid tumors including CRC based on DESTINY-CRC02 data (38% response rate, 5.8-month median PFS), with efficacy even in RAS-mutant cases; interstitial lung disease occurred in 26% of Japanese patients. (Gan To Kagaku Ryoho)
Trastuzumab deruxtecan approved in Japan for HER2-positive CRC
The CRC Digest